1-4 of 4
Juliana Biondo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments

Arliene Ravelo, Kelley Myers, Robyn Brumble, Cooper Bussberg, Brian Koffman, Beenish S. Manzoor, Juliana Biondo, Carol Mansfield
Journal: Blood
Blood (2022) 140 (Supplement 1): 10803–10805.
https://doi.org/10.1182/blood-2022-159648
Published: 2022
Journal Articles

Real-World Assessment of Second Primary Malignancies in a Treated and Untreated Chronic Lymphocytic Leukemia Population in the United States

Sikander Ailawadhi, Arliene Ravelo, Carmen Ng, Bonny Shah, Rongrong Wang, Katherine Eakle, Juliana Biondo
Journal: Blood
Blood (2022) 140 (Supplement 1): 8040–8041.
https://doi.org/10.1182/blood-2022-158139
Published: 2022
Journal Articles

Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD PhD, Matthew S Davids, Julie Chang, Shuo Ma, MD PhD, Juliana Biondo, Mehrdad Mobasher, MD MPH, Yong Mun, PhD, Anthony R Mato, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5556.
https://doi.org/10.1182/blood-2018-99-116942
Published: 2018
Journal Articles

Patterns of Ibrutinib Use, Discontinuation, and Hospitalization Among Patients with Chronic Lymphocytic Leukemia (CLL) in a US Healthcare Claims Database

Tu My To, PhD MPH, Wei-Shi Yeh, PhD MS, Juliana Biondo, Anthony S Masaquel, PhD MPH
Journal: Blood
Blood (2018) 132 (Supplement 1): 5909.
https://doi.org/10.1182/blood-2018-99-112679
Published: 2018